Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Work In Process (2022 - 2026)

Ekso Bionics Holdings has reported Work In Process over the past 4 years, most recently at $102000.0 for Q4 2025.

  • On a quarterly basis, Work In Process fell 42.37% to $102000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $102000.0, a 42.37% decrease, with the full-year FY2025 number at $102000.0, down 42.37% from a year prior.
  • Work In Process reached $102000.0 in Q4 2025 per EKSO's latest filing, down from $324000.0 in the prior quarter.
  • The five-year high for Work In Process was $751000.0 in Q2 2023, with the low at $102000.0 in Q4 2025.
  • The 4-year median for Work In Process is $310000.0 (2024), against an average of $332833.3.
  • Peak YoY movement for Work In Process: crashed 71.11% in 2024, then surged 38.25% in 2025.
  • Tracing EKSO's Work In Process over 4 years: stood at $487000.0 in 2022, then crashed by 40.45% to $290000.0 in 2023, then plummeted by 38.97% to $177000.0 in 2024, then tumbled by 42.37% to $102000.0 in 2025.
  • According to Business Quant data, Work In Process over the past three periods came in at $102000.0, $324000.0, and $300000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.